---
title: Momelotinib for the treatment of myelofibrosis
date: '2024-07-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38958484/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240704182601&v=2.18.0.post9+e462414
source: Blood
description: In September 2023, the Food and Drug Administration approved momelotinib
  for the treatment of myelofibrosis (MF) with anemia, marking the fourth US regulatory
  approval of a Janus kinase (JAK) inhibitor for MF. A positive opinion from the European
  Medicines Agency followed in November 2023. Momelotinib's ability to address splenomegaly,
  symptoms and anemia, including in thrombocytopenic patients (platelets ≥25 x 109/L),
  the ease of switching from ruxolitinib, and good tolerability ...
disable_comments: true
---
In September 2023, the Food and Drug Administration approved momelotinib for the treatment of myelofibrosis (MF) with anemia, marking the fourth US regulatory approval of a Janus kinase (JAK) inhibitor for MF. A positive opinion from the European Medicines Agency followed in November 2023. Momelotinib's ability to address splenomegaly, symptoms and anemia, including in thrombocytopenic patients (platelets ≥25 x 109/L), the ease of switching from ruxolitinib, and good tolerability ...